Cargando…

Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018

BACKGROUND: Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS region in the world Atlas of MS 2013.This study aimed to investigate the prevale...

Descripción completa

Detalles Bibliográficos
Autores principales: Baghbanian, Seyed Mohammad, Cheraghmakani, Hamed, HabibiSaravi, Reza, Azar, Arash, Ghasemihamedani, Fariba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017621/
https://www.ncbi.nlm.nih.gov/pubmed/32050931
http://dx.doi.org/10.1186/s12883-020-1618-6
_version_ 1783497231845818368
author Baghbanian, Seyed Mohammad
Cheraghmakani, Hamed
HabibiSaravi, Reza
Azar, Arash
Ghasemihamedani, Fariba
author_facet Baghbanian, Seyed Mohammad
Cheraghmakani, Hamed
HabibiSaravi, Reza
Azar, Arash
Ghasemihamedani, Fariba
author_sort Baghbanian, Seyed Mohammad
collection PubMed
description BACKGROUND: Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS region in the world Atlas of MS 2013.This study aimed to investigate the prevalence of MS in Mazandaran province after 12 years and the need for possible changes in the global map of the prevalence of MS. METHODS: We included all MS patients living in Mazandaran province in 2018 in this descriptive cross-sectional study. We updated our pre-existing registration questionnaires which included demographic information and medical data of MS patients by interview. We obtained the demographic profile of Mazandaran province from the most recent census in 2016 and the National Civil Registry of the Mazandaran province for calculating prevalence of MS. RESULTS: The total number of MS patients in Mazandaran was 2418 (25.8% male and 74.2% female) with a female to male ratio of 2.9. Based on the local population of 3,332,556, (50.4% male and 49.6% female), this study showed a prevalence of 72.5 per 100,000 for MS in this region. The prevalence of this disease by gender was 37.1 per 100,000 for men and 108.5 per 100,000 for women. The mean (SD) age of the patients at the time of the study was 38.5 (10.1) years with a minimum of 15 and a maximum of 75 years. The most common type of MS was Relapsing-Remitting MS with 86%. CONCLUSIONS: All recent studies showed significant upward trend in the prevalence of MS around the world. Based on the results of our study and many other studies in Iran, the Atlas of MS prevalence map needs to be update. Iran’s status should be changed to the high-prevalence of MS in the new Atlas. Due to the increasing prevalence of MS, we suggest an adjustment in the Global MS Prevalence Scale.
format Online
Article
Text
id pubmed-7017621
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70176212020-02-20 Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018 Baghbanian, Seyed Mohammad Cheraghmakani, Hamed HabibiSaravi, Reza Azar, Arash Ghasemihamedani, Fariba BMC Neurol Research Article BACKGROUND: Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS region in the world Atlas of MS 2013.This study aimed to investigate the prevalence of MS in Mazandaran province after 12 years and the need for possible changes in the global map of the prevalence of MS. METHODS: We included all MS patients living in Mazandaran province in 2018 in this descriptive cross-sectional study. We updated our pre-existing registration questionnaires which included demographic information and medical data of MS patients by interview. We obtained the demographic profile of Mazandaran province from the most recent census in 2016 and the National Civil Registry of the Mazandaran province for calculating prevalence of MS. RESULTS: The total number of MS patients in Mazandaran was 2418 (25.8% male and 74.2% female) with a female to male ratio of 2.9. Based on the local population of 3,332,556, (50.4% male and 49.6% female), this study showed a prevalence of 72.5 per 100,000 for MS in this region. The prevalence of this disease by gender was 37.1 per 100,000 for men and 108.5 per 100,000 for women. The mean (SD) age of the patients at the time of the study was 38.5 (10.1) years with a minimum of 15 and a maximum of 75 years. The most common type of MS was Relapsing-Remitting MS with 86%. CONCLUSIONS: All recent studies showed significant upward trend in the prevalence of MS around the world. Based on the results of our study and many other studies in Iran, the Atlas of MS prevalence map needs to be update. Iran’s status should be changed to the high-prevalence of MS in the new Atlas. Due to the increasing prevalence of MS, we suggest an adjustment in the Global MS Prevalence Scale. BioMed Central 2020-02-12 /pmc/articles/PMC7017621/ /pubmed/32050931 http://dx.doi.org/10.1186/s12883-020-1618-6 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Baghbanian, Seyed Mohammad
Cheraghmakani, Hamed
HabibiSaravi, Reza
Azar, Arash
Ghasemihamedani, Fariba
Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title_full Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title_fullStr Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title_full_unstemmed Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title_short Does the multiple sclerosis (MS) map need to change again? An update of MS prevalence in Mazandaran province of Iran in 2018
title_sort does the multiple sclerosis (ms) map need to change again? an update of ms prevalence in mazandaran province of iran in 2018
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017621/
https://www.ncbi.nlm.nih.gov/pubmed/32050931
http://dx.doi.org/10.1186/s12883-020-1618-6
work_keys_str_mv AT baghbanianseyedmohammad doesthemultiplesclerosismsmapneedtochangeagainanupdateofmsprevalenceinmazandaranprovinceofiranin2018
AT cheraghmakanihamed doesthemultiplesclerosismsmapneedtochangeagainanupdateofmsprevalenceinmazandaranprovinceofiranin2018
AT habibisaravireza doesthemultiplesclerosismsmapneedtochangeagainanupdateofmsprevalenceinmazandaranprovinceofiranin2018
AT azararash doesthemultiplesclerosismsmapneedtochangeagainanupdateofmsprevalenceinmazandaranprovinceofiranin2018
AT ghasemihamedanifariba doesthemultiplesclerosismsmapneedtochangeagainanupdateofmsprevalenceinmazandaranprovinceofiranin2018